Regeneus
(ASX:RGS) has announced the commencement of a trial of its cancer vaccine technology Kvax, in combination with chemotherapy as a treatment of canine lymphoma.
Veterinary Oncologists at the Small Animal Specialist Hospital in Sydney will conduct the trial.
The trial will use Kvax together with chemotherapy to seek to extend remission times for 45 dogs with lymphoma.
Once in remission, the dog may then be treated with Kvax.
Lymphoma is the most commonly treated cancer in dogs.
Regeneus reported a loss of $6.6 million at 30 June 2015.
